RET Gene Mutations: Linked Conditions and Clinical Trials

The RET gene sits on chromosome 10q11.21, and its full name is ret proto-oncogene. Orphanet links RET to 10 rare conditions and lists variants in the gene as a cause of 7 of them. Trial Friend's RET Fusion Cancer, Medullary Thyroid Cancer, Familial Medullary Thyroid Carcinoma and Pheochromocytoma pages list RET among the genes behind each condition. As of September 29, 2026, 24 recruiting or soon-opening trials on ClinicalTrials.gov name RET as a gene.

Other symbols for RET in gene databases: CDHF12, CDHR16, PTC, RET51.

See the trialsSearch another gene

What the RET gene does

RET makes a receptor that spans the cell membrane and passes growth signals into the cell. It is needed for normal development of certain nerve cells, including nerves in the intestine, and for kidney development.

Summarized from the RET page on MedlinePlus Genetics, U.S. National Library of Medicine, checked September 29, 2026.

Conditions linked to RET on Trial Friend

These condition pages list RET among the genes behind the condition, checked against genetics references when each page was written.

RET Fusion CancerRET fusion

Somatic RET fusions occur in about 1 to 2% of non-small cell lung cancers and in some thyroid cancers; germline RET variants cause MEN2, a separate entity.

Medullary Thyroid Cancer

About 20-30% of all MTC carries a germline RET variant (MEN2/FMTC), so germline RET testing is advised for every MTC patient; 40-50% of sporadic tumors have a somatic RET variant, most often M918T.

Familial Medullary Thyroid Carcinoma

One disease-causing variant can be enough to cause the condition.

FMTC is the MTC-only end of the MEN2A spectrum; the RET codon involved predicts risk level and the recommended age for prophylactic thyroidectomy.

Pheochromocytoma

One disease-causing variant can be enough to cause the condition.

About 35% of cases are hereditary, so germline panel testing is recommended for essentially all patients.

RET mutation clinical trials

These recruiting or soon-opening trials mention RET as a gene in their title, summary, eligibility rules or keywords. Some want people with a variant in it, and others study it more broadly, which is why each trial's own words are shown. In cancer trials the gene change is usually one found in the tumor rather than one a person inherited.

24 trials, checked September 29, 2026. The list refreshes from ClinicalTrials.gov every few hours.

RecruitingNCT06530316
RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer
Thyroid Cancer
Why it's listed: “RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer”
RecruitingPhase 1, Phase 2NCT05451602
HEC169096 in Participants With Advanced Solid Tumors
Advanced Solid Tumor
Why it's listed: “Phase 2: All participants must have an oncogenic RET-rearrangement/fusion or mutation (excluding synonymous, frameshift, and nonsense mutations) solid tumor…”
RecruitingPhase 2NCT06563999
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
Lung Cancer Stage III · Mutation
Why it's listed: “…ld have a rare mutation based on NGS, including mutations of EGFR exon20ins, ROS1 fusion, RET fusion, NTRK fusion, MET 14 exon, HER2, BRAF V600E, KRAS G12C, and ALK fusion.”
RecruitingPhase 1, Phase 2NCT05443126
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
NSCLC
Why it's listed: “A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies”
RecruitingPhase 2NCT04302025
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Why it's listed: “…e following abnormalities: ALK fusion, ROS1 fusion, NTRK1/2/3 fusion; BRAF V600 mutation, RET fusion, PD-L1 expression in ≥ 1% tumor cells as determined by Food and Drug Administration (FDA)…”
RecruitingPhase 1NCT05142189
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Why it's listed: “Participants' NSCLC must have ALK rearrangement or RET rearrangement.”
RecruitingPhase 3NCT07809256
A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation
NSCLC (Non-small Cell Lung Cancer)R
Why it's listed: “…vatinib in adults with metastatic non-small cell lung cancer (NSCLC) who have a confirmed RET gene rearrangement and whose disease has progressed after one or more previous systemic treatments.”
RecruitingPhase 1, Phase 2NCT06109558
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
Non Small Cell Lung Cancer · RET Gene Mutation · MET Amplification
Why it's listed: “Cohort A:MET amplification,(by FISH, NGS or IHC) Cohort B:RET fusion.”
RecruitingPhase 1, Phase 2NCT06081907
The Efficacy and Safety of IBI363 in Solid Tumors
Advanced Solid Tumor
Why it's listed: “…tations, including but not limited to ROS1, BRAF V600E, METex14 skipping, HER2, NTRK, and RET fusion.”
RecruitingPhase 2NCT01639508
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Non-Small Cell Lung Cancer
Why it's listed: “…cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity.”
RecruitingPhase 2NCT06147570
A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Nonsmall Cell Lung Cancer
Why it's listed: “…e of this study is to investigate the efficacy and safety of HS-10365 in Chinese advanced RET fusion-positive non-small cell lung cancer patients without any systemic therapy.”
RecruitingPhase 2NCT06458036
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Differentiated Thyroid Cancer · Pediatric Cancer · Cancer
Why it's listed: “Identification of an activating RET gene alteration (fusion or mutation). The RET alteration result should be generated from a laboratory wit…”
RecruitingPhase 2NCT05800340
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Non-Small Cell Lung Cancer · RET Driver Mutation · BRAF V600 Mutation
Why it's listed: “…irmed diagnosis with Stage IIB-IIIB NSCLC which harbored rare driver alteration including RET fusions, BRAF (V600E or non-V600E but confirmed driver mutations), ERBB2 exon20 insertion, MET am…”
RecruitingPhase 1, Phase 2NCT04683250
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
RET-altered Non Small Cell Lung Cancer · RET-altered Solid Tumors
Why it's listed: “…harmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify th…”
RecruitingPhase 4NCT07704658
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
NSCLC (Non-small Cell Lung Cancer) · Thyroid Cancer · Solid Tumor Malignancies
Why it's listed: “…has relapsed after, or is not responsive to, standard therapies and harbors an oncogenic RET fusion or mutation as determined by a validated test.”
RecruitingPhase 2NCT05668962
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Thyroid Cancer · Thyroid Carcinoma · Metastatic Thyroid Cancer
Why it's listed: “…estore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer.”
Opening soonNCT07042984
RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer
Papillary Thyroid Carcinoma · Thyroid Neoplasms · RET Proto-Oncogene Mutation
Why it's listed: “Why is this study being done? RET gene alterations occur in only 5-10 % of papillary thyroid cancers, but they can change how surgeons treat…”
Opening soonNCT07418879
A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC
Non-small Cell Lung Cancer · RET Fusion · Pralsetinib
Why it's listed: “A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC”
Opening soonNCT07048964
A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations
Medullary Thyroid Cancer (MTC)
Why it's listed: “…dy. For patients with locally advanced and/or metastatic medullary thyroid carcinoma with RET gene mutations who require systemic treatment, they are randomly assigned to either the Pralsetinib or A…”
Opening soonPhase 2NCT07829744
Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations
Lung Cancer (NSCLC)
Why it's listed: “…umented EGFR exon 20 insertion, ALK fusion, ROS1 fusion, MET exon 14 skipping alteration, RET fusion, or KRAS G12C mutation.”
Opening soonPhase 4NCT07010393
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
Thyroid Neoplasms
Why it's listed: “…tests whether genomically matched neoadjuvant therapy (1-4 cycles tailored to BRAF V600E, RET fusion/mutation, isolated TERT mutation, triple-negative BRAF/RET/TERT, or ICI ± TKI) can render…”
Opening soonPhase 4NCT07822880
A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India
Thyroid Neoplasms · Carcinoma, Non-Small-Cell Lung
Why it's listed: “This study will evaluate the safety of selpercatinib in participants with RET-altered cancers in India. The study will also assess the number of changes and why participants s…”
Opening soonNCT07612293
STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection
Thyroid Gland Medullary Carcinoma
Why it's listed: “…id tissue and that they may be able to be managed differently than patients with germline RET mutations. Thyroid lobectomy with ipsilateral central neck dissection is a surgical procedure which…”
Opening soonPhase 2NCT07416058
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
Lung Adenocarcinoma
Why it's listed: “…are available; these mutations are stratified as follows: EGFR (19del, L858R); ALK, ROS1, RET fusions; KRAS G12C; BRAF V600; and HER2 exon 20 insertions. Patients must have disease progressio…”

All conditions linked to RET gene mutations

Orphanet records how each gene relates to each condition. Orphanet links RET to 10 rare conditions and lists variants in the gene as a cause of 7 of them.

  • Causes it. Disease-causing variants in this gene are a direct cause of the condition.
  • Raises risk. Some variants raise the chance of the condition without guaranteeing it.
  • Being studied. Researchers suspect a role that isn't confirmed yet.
  • Fusion gene. The gene is part of an abnormal fusion found in the tumor, not usually inherited.
Isolated familial medullary thyroid carcinomaCauses itTrial Friend pageOrphanet
Sporadic pheochromocytoma/secreting paragangliomaRaises riskTrial Friend pageOrphanet
Hereditary pheochromocytoma-paragangliomaBeing studiedTrial Friend pageOrphanet
Haddad syndromeCauses itOrphanet
Hirschsprung diseaseCauses itOrphanet
Multiple endocrine neoplasia type 2ACauses itOrphanet
Multiple endocrine neoplasia type 2BCauses itOrphanet
Renal agenesis, bilateralCauses itOrphanet
Renal agenesis, unilateralCauses itOrphanet
Differentiated thyroid carcinomaFusion geneOrphanet

RET genetic test results and what a variant can mean

Labs sort each variant they find into 5 groups, from pathogenic and likely pathogenic through uncertain significance to likely benign and benign. Only the first 2 are usually treated as the cause of a condition. A variant of uncertain significance, or VUS, is one without enough evidence either way yet, and labs can reclassify it as research builds.

A genetic counselor or your doctor can explain what a specific result means for you and your family. Our genetic testing guide covers the terms, and MedlinePlus Genetics from the National Library of Medicine has a plain-language page on RET.

RET gene questions

What does the RET gene do?

RET makes a receptor that spans the cell membrane and passes growth signals into the cell. It is needed for normal development of certain nerve cells, including nerves in the intestine, and for kidney development. This summary follows MedlinePlus Genetics from the U.S. National Library of Medicine.

Are there clinical trials for people with RET gene variants?

As of September 29, 2026, 24 recruiting or soon-opening trials on ClinicalTrials.gov name RET as a gene. Each one is listed on this page with the words from the trial that mention the gene. ClinicalTrials.gov also lists 10 open trials for RET Fusion Cancer, 27 for Medullary Thyroid Cancer, 2 for Familial Medullary Thyroid Carcinoma and 44 for Pheochromocytoma, and Match Me on Trial Friend can check those against age, sex, location and treatment history.

What conditions are linked to the RET gene?

Orphanet links RET to 10 rare conditions and lists variants in the gene as a cause of 7 of them. They include Isolated familial medullary thyroid carcinoma, Sporadic pheochromocytoma/secreting paraganglioma, Hereditary pheochromocytoma-paraganglioma, Haddad syndrome, Hirschsprung disease, Multiple endocrine neoplasia type 2A and 4 more. Orphanet is the European rare disease database run by INSERM in Paris.

Is RET Fusion Cancer inherited?

Somatic RET fusions occur in about 1 to 2% of non-small cell lung cancers and in some thyroid cancers; germline RET variants cause MEN2, a separate entity.

Is Medullary Thyroid Cancer inherited?

About 20-30% of all MTC carries a germline RET variant (MEN2/FMTC), so germline RET testing is advised for every MTC patient; 40-50% of sporadic tumors have a somatic RET variant, most often M918T.

What does a RET variant of uncertain significance mean?

A variant of uncertain significance, or VUS, is a change in the gene that labs don't yet have enough evidence to call disease-causing or harmless. It is not used on its own to diagnose a condition, and labs can reclassify it as research builds. A genetic counselor can explain what a specific result means for you and your family.

Sources

  • Gene and condition links from Orphadata (Orphanet, INSERM US14), used under CC BY 4.0, read September 29, 2026.
  • Trials from ClinicalTrials.gov, read September 29, 2026.
  • RET gene, MedlinePlus Genetics, U.S. National Library of Medicine.
  • Inheritance and gene notes from the Trial Friend condition pages above, each checked against genetics references.

Other gene pages

The gene search covers every gene Orphanet links to a rare disease.